{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T14:16:14Z","timestamp":1725891374354},"publisher-location":"Berlin, Heidelberg","reference-count":20,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642780127"},{"type":"electronic","value":"9783642780103"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1993]]},"DOI":"10.1007\/978-3-642-78010-3_21","type":"book-chapter","created":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T23:39:01Z","timestamp":1343518741000},"page":"230-237","source":"Crossref","is-referenced-by-count":2,"title":["Disposition of the Neuroleptics Perphenazine, Zuclopenthixol, and Haloperidol Cosegregates with Polymorphic Debrisoquine Hydroxylation"],"prefix":"10.1007","author":[{"given":"L.","family":"Bertilsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ekqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Llerena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"21_CR1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1600-0447.1981.tb00815.x","volume":"294","author":"T Aaes-J\u00f8rgensen","year":"1981","unstructured":"Aaes-J\u00f8rgensen T, Gravem A, J\u00f8rgensen A (1981) Serum levels of the isomers of clopenthixol in patients given cis (Z)-clopenthixol or cis(Z)\/trans(E)-clopenthixol. Acta Psychiatr Scand 64 Suppl 294: 70\u201377","journal-title":"Acta Psychiatr Scand 64 Suppl"},{"key":"21_CR2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1988.01800250095013","volume":"45","author":"RJ Baldessarini","year":"1988","unstructured":"Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 79\u201391","journal-title":"Arch Gen Psychiatry"},{"key":"21_CR3","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/00007691-198512000-00021","volume":"7","author":"L Bertilsson","year":"1985","unstructured":"Bertilsson L, \u00c5berg-Wistedt A, Gustafsson LL, Nordin C (1985) Extremely rapid hydroxylation of debrisoquine - a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 7: 478\u2013480","journal-title":"Ther Drug Monit"},{"key":"21_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF00426481","volume":"53","author":"L Bolvig Hansen","year":"1977","unstructured":"Bolvig Hansen L, Larsen NE (1977) Plasma concentrations of perhenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology (Berl) 53: 127\u2013130","journal-title":"Psychopharmacology (Berl)"},{"key":"21_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/BF00432736","volume":"74","author":"L Bolvig Hansen","year":"1981","unstructured":"Bolvig Hansen L, Larsen NE, Vesterg\u00e5rd P (1981) Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology (Berl) 74: 306\u2013309","journal-title":"Psychopharmacology (Berl)"},{"key":"21_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/BF00637732","volume":"36","author":"K Br\u00f8sen","year":"1989","unstructured":"Br\u00f8sen K, Gram LF (1989) Clinical significance of the sparteine\/debrisoquine oxidation polymorphism. Eur J Chn Pharmacol 36: 537\u2013547","journal-title":"Eur J Chn Pharmacol"},{"key":"21_CR7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00609423","volume":"37","author":"BS Chakraborty","year":"1989","unstructured":"Chakraborty BS, Hubbard JW, Hawes EM, McKay G, Cooper JK, Gurnsey T, Korchinski ED, Midha KK (1989) Interconversion between haloperidol and reduced haloperidol in healthy volunteers. Eur J Chn Pharmacol 37: 45\u201348","journal-title":"Eur J Chn Pharmacol"},{"key":"21_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2165\/00003088-198611010-00003","volume":"11","author":"SG Dahl","year":"1986","unstructured":"Dahl SG (1986) Plasma level monitoring of antipsychotic drugs. Clinical utility. Clinn Pharmacokinet 11: 36\u201361","journal-title":"Clinn Pharmacokinet"},{"key":"21_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1600-0447.1991.tb01428.x","volume":"84","author":"M-L Dahl","year":"1991","unstructured":"Dahl M-L, Ekqvist B, Widen J, Bertilsson L (1991) Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 84: 99\u2013102","journal-title":"Acta Psychiatr Scand"},{"key":"21_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/clpt.1989.109","volume":"46","author":"M-L Dahl-Puustinen","year":"1989","unstructured":"Dahl-Puustinen M-L, Lid\u00e9n A, Aim C, Nordin C, Bertilsson L (1989) Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation in human beings. Clin Pharmacol Ther 46: 78\u201381","journal-title":"Clin Pharmacol Ther"},{"key":"21_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/jmg.17.2.102","volume":"17","author":"DAP Evans","year":"1980","unstructured":"Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102\u2013105","journal-title":"J Med Genet"},{"key":"21_CR12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2165\/00003088-198917060-00004","volume":"17","author":"JS Froemming","year":"1989","unstructured":"Froemming JS, Francis Lam YW, Jann MW, Davis CM (1989) Pharmacokinetics of haloperidol. Clin Pharmacokinet 17: 396\u2013423","journal-title":"Clin Pharmacokinet"},{"key":"21_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/00007691-199204000-00003","volume":"14","author":"A Llerena","year":"1992","unstructured":"Llerena A, Alm C, Dahl M-L, Ekqvist B, Bertilsson L (1992a) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14: 92\u201397","journal-title":"Ther Drug Monit"},{"key":"21_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/00007691-199206000-00014","volume":"14","author":"A Llerena","year":"1992","unstructured":"Llerena A, Dahl M-L, Ekqvist B, Bertilsson L (1992b) Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 14: 261\u2013264","journal-title":"Ther Drug Monit"},{"key":"21_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/0024-3205(83)90315-6","volume":"32","author":"SV Otton","year":"1983","unstructured":"Otton SV, Inaba T, Kalow W (1983) Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci 32: 795\u2013800","journal-title":"Life Sci"},{"key":"21_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/clpt.1988.176","volume":"44","author":"E Steiner","year":"1988","unstructured":"Steiner E, Bertilsson L, S\u00e4we J, Bertling I, Sj\u00f6qvist F (1988) Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44: 431\u2013435","journal-title":"Clin Pharmacol Ther"},{"key":"21_CR17","first-page":"89","volume":"22","author":"EKG Syv\u00e4lahti","year":"1986","unstructured":"Syv\u00e4lahti EKG, Lindberg R, Kallio J, de Vocht M (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Chn Pharmacol 22: 89\u201392","journal-title":"Br J Chn Pharmacol"},{"key":"21_CR18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2125.1991.tb05588.x","volume":"31","author":"RF Tyndale","year":"1991","unstructured":"Tyndale RF, Kalow W, Inaba T (1991) Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine\/debrisoquine monooxygenase). Br J Chn Pharmacol 31: 655\u2013660","journal-title":"Br J Chn Pharmacol"},{"key":"21_CR19","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1016\/0006-2952(85)90533-7","volume":"34","author":"C Bahr Von","year":"1985","unstructured":"Von Bahr C, Spina E, Birgersson C, Ericsson \u00d6, G\u00f6ransson M, Henthora T, Sj\u00f6qvist F (1985) Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 34: 2501\u20132505","journal-title":"Biochem Pharmacol"},{"key":"21_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/clpt.1991.22","volume":"49","author":"C Bahr Von","year":"1991","unstructured":"Von Bahr C, Movin G, Nordin C, Lid\u00e9n A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sj\u00f6qvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 49: 234\u2013240","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Pharmacology in Psychiatry"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-78010-3_21.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T21:23:03Z","timestamp":1687641783000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-78010-3_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993]]},"ISBN":["9783642780127","9783642780103"],"references-count":20,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-78010-3_21","relation":{},"subject":[],"published":{"date-parts":[[1993]]}}}